Cite
HARVARD Citation
De Giorgi, U. et al. (2021). Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. European journal of cancer. pp. 237-246. [Online].